Skip to main content
Premium Trial:

Request an Annual Quote

Sequenom Hopes to Net $28M From Private Stock Placement

NEW YORK (GenomeWeb News) — Sequenom said today it hopes to net $28 million in a private placement of 3.4 million shares of common stock at $9 apiece.   

The company said it plans to use the money to research, develop, and commercialize “various diagnostic tests,” and for general corporate purposes.

Sequenom also reaffirmed its full-year 2007 revenue guidance of $39 million to $41 million, which would be an increase of between 37 percent and 44 percent over 2006 revenues.

The company said Lehman Brothers and UBS Investment Bank were joint-lead placement agents in the private placement and Oppenheimer & Co., Leerink Swann, and Rodman & Renshaw were co-placement agents.

The Scan

Science Confidence Boost

The New York Times reports that a new poll finds trust in science and scientists has increased with the COVID-19 pandemic.

Appeal and Funds

Some grant applications denied funding due to an Australian Research Council rule change have now been funded following an appeal, the Guardian reports.

Surveillance for Variants

Vox writes that the detection of the Omicron SARS-CoV-2 variant highlights the need for improved viral genomic surveillance.

Nature Papers Examine Taxonomic Gaps in Plant Sequencing, SARS-CoV-2-Human Interactome

In Nature this week: plant genome sequencing dominated by affluent countries, and more.